As mentioned in the update on Dep Cabazitaxel
One patient with stage III cholangiocarcinoma (the second most common liver cancer which is often fatal) achieved a 76% decrease in a tumour biomarker after two cycles of DEP® cabazitaxel.
The cancer is typically incurable at diagnosis
I looked up cholangiocarcinoma on Wikipedia for an understanding of the cancer
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts.[2] Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever.[1] Light colored stool or dark urine may also occur.[4] Other biliary tract cancers include gallbladder cancer and cancer of the ampulla of Vater.[7]
Risk factors for cholangiocarcinoma include primary sclerosing cholangitis (an inflammatory disease of the bile ducts), ulcerative colitis, cirrhosis, hepatitis C, hepatitis B, infection with certain liver fluke, and some congenital liver malformations.[1][3][8] However, most people have no identifiable risk factors.[3] The diagnosis is suspected based on a combination of blood tests, medical imaging, endoscopy, and sometimes surgical exploration.[4] The disease is confirmed by examination of cells from the tumor under a microscope.[4] It is typically an adenocarcinoma (a cancer that forms glands or secretes mucin).[3]
Cholangiocarcinoma is typically incurable at diagnosis.[1] In these cases palliative treatments may include surgical resection, chemotherapy, radiation therapy, and stenting procedures.[1] In about a third of cases involving the common bile duct and less commonly with other locations the tumor can be completely removed by surgery offering a chance of a cure.[1] Even when surgical removal is successful chemotherapy and radiation therapy are generally recommended.[1] In certain cases surgery may include a liver transplantation.[3] Even when surgery is successful 5-year survival is typically less than 50%.[6]
Cholangiocarcinoma is rare in the Western world, with estimates of it occurring in 0.5–2 people per 100,000 per year.[1][6] Rates are higher in South-East Asia where liver flukes are common.[5] Rates in parts of Thailand are 60 per 100,000 per year.[5] It typically occurs in people in their 70s, however in those with primary sclerosing cholangitis it often occurs in the 40s.[3] Rates of cholangiocarcinoma within the liver in the Western world have increased.[6]
- Forums
- ASX - By Stock
- Dep Cabazitaxel effective against stage III cholangiocarcinoma
As mentioned in the update on Dep Cabazitaxel One patient with...
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.48M |
Open | High | Low | Value | Volume |
9.9¢ | 9.9¢ | 9.5¢ | $35.24K | 364.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 18326 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.8¢ | 15262 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 8326 | 0.095 |
3 | 160000 | 0.094 |
2 | 134306 | 0.092 |
3 | 81442 | 0.090 |
1 | 30000 | 0.089 |
Price($) | Vol. | No. |
---|---|---|
0.098 | 5000 | 1 |
0.100 | 38876 | 3 |
0.105 | 199768 | 2 |
0.110 | 168286 | 9 |
0.115 | 85453 | 2 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
SPL (ASX) Chart |